ARE THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDELINES THAT PROMULGATE ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER JUSTIFIED BY THE AVAILABLE EVIDENCE?

Authors


Roger Kirby, The Prostate Centre, 32 Wimpole Street London W1G 8GT, UK.
e-mail: bjui@theprostatecentre.com

No abstract is available for this article.

Ancillary